Revolutionary new peanut allergy treatment received FDA approval
The Federal Drug Administration has approved, for the first time, a treatment developed by biopharmaceutical company Aimmune Therapeutics from California, which has shown tremendous promise in alleviating peanut allergies in children and adolescents, with almost two-thirds of 372 children showing tolerance for the small amounts of peanut protein in two peanuts.
california tolerance drug company protein peanut allergy aimmune therapeutics approve fda
ScienceNewsRelated Articles
Elon Musk's $700 million jackpot
Elon Musk's $700 million jackpot
Tesla CEO Elon Musk has qualified for a compensation package worth about $770 million after the electric vehicle company hit certain goals reflecting its rapid growth in recent years. The company said he had received the right to buy about 1.688 million shares of Tesla stock at a price of $350.02, which is where the stock was trading when the compensation package was set.
elon company package
Usatoday
US Surgeon General warns the COVID-19 pandemic is about to get worse
Appearing on NBC's The Today Show, US Surgeon General Jerome Adams has stated that the coronavirus pandemic is about to get worse this week, with most states in the country facing an alarming rise in the number of newly infected people. The statement comes as New York, New Jersey, California, Connecticut, Oregon and Illinois have seen complete lockdowns, with New York accounting for 6 percent of the world's coronavirus cases.
new-york california nbc outbreak lockdown general surgeon coronavirus pandemic illinois covid-19 new-jersey today-show jerome-adams connecticut oregon
CIDRAP
Malaria medication could be a cure for coronavirus, research finds
Researchers led by infectious disease expert Didier Raoult have found that the drug hydroxychloroquine, used in the treatment of malaria, could potentially be a cure for the novel coronavirus, with a lab experiment involving 26 patients revealing more than 50 percent of coronavirus-positive patients tested negative for COVID-19 after a week of treatment with hydroxychloroquine.
research negative experiment disease drug medication positive cure coronavirus infectious treatment covid-19 didier-raoult hydroxychloroquine
WashingtonExaminer
COVID-19 can survive on surfaces for days, hours in the air
A new study from the National Institute of Allergy and Infectious Diseases, which forms part of the US National Institutes of Health, has discovered that the extremely contagious novel coronavirus COVID-19 can survive in the air and remain infectious for up to three hours, on cardboard surfaces for no more than 24 hours, on copper for 4 hours, and on stainless steel surfaces for about 6 hours.
health disease national united-states air contagious institute coronavirus infectious surface pandemic allergy covid-19 copper cardboard stainless-steel novel
Reuters